Therapy Areas: Central Nervous System
Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology Congress
7 October 2022 - - US-based biopharmaceutical company Karuna Therapeutics, Inc. (NASDAQ: KRTX) will share data from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia at the 35th European College of Neuropsychopharmacology Congress, to be held October 15-18, 2022, in Vienna, Austria, the company said.

A poster presentation and symposium will include previously reported efficacy and safety data, as well as new additional safety data from the trial.

KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer's disease.

Comprised of muscarinic agonist xanomeline and muscarinic antagonist trospium, it is designed to preferentially stimulate muscarinic receptors in the central nervous system.

The company said that KarXT is the first potential medicine of its kind with a new and unique dual mechanism that does not rely on the dopaminergic or serotonergic pathway to treat symptoms of serious mental illness.

This approach has the potential to provide a differentiated therapy, and, if approved, to beneficially impact the lives of millions of people with serious mental illness.

Schizophrenia is a chronic and often debilitating mental illness that impacts how one thinks, feels, and behaves.

It is characterized by positive symptoms (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment.

Together these symptoms can severely impact quality of life and productivity, with only 10% of people gainfully employed and many struggling to meet adult milestones such as living independently.

The life expectancy of people living with schizophrenia is reduced by 10-20 years compared to the general population.

Schizophrenia affects approximately 21 m people worldwide and is most commonly treated with antipsychotics.

Unfortunately, many people with schizophrenia continue to experience limited efficacy or problematic side effects while on antipsychotic therapy, and up to 74% of patients discontinue medication before 18 months.

When schizophrenia treatment is discontinued, it can lead to impacts on health including relapse, hospitalization, and longer time to remission.

Karuna Therapeutics is a clinical-stage biopharmaceutical company.
Login
Username:

Password: